3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
28
Breast
20
Genitourinary
18
Gastrointestinal
14
Thoracic
10
Sarcoma
6
Tumor-Agnostic
4
Other solid neoplasm
4
Endocrine
4
CNS
4
NET
3
Lymphoid
3
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Head & Neck
2
Dermatologic
1
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Neoplasms
1
Interventions
Dexamethasone
124
daratumumab
73
Lenalidomide
72
Bortezomib
61
pomalidomide
45
Cyclophosphamide
41
carfilzomib
40
Calcium Dobesilate
36
Specimen Handling
34
Biopsy
30
Magnetic Resonance Spectroscopy
27
belantamab mafodotin
24
isatuximab
20
fludarabine
20
dexamethasone acetate
18
dexamethasone 21-phosphate
18
auricularum
18
Melphalan
18
talquetamab
16
iberdomide
16
fludarabine phosphate
12
selinexor
11
elotuzumab
10
X-Rays
10
tocilizumab
9
Nivolumab
8
Sirolimus
7
Crizotinib
7
trametinib
6
Whole-Body Irradiation
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
olaparib
×
Plasma cell
×
90 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled